| Date:   | 2022/01      | /20  |
|---------|--------------|--|
| Your Na | ame:         | Dehua Sun  |
| Manuso  | cript Title: | _Screening for malignant tumor cells in serous effusions with an automatic hematology analyzer |
| using a | novel diagr  | ostic algorithm  |
| Manuso  | cript numbe  | r (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert<br>testimony  | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or pending   | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:     | 2022/01/20                              |            |   |
|-----------|---|------------|---|
| Your Nar  | me: Xinru Mao                           |            |   |
| Manuscr   | ript Title: <u>Screening for mali</u> g | nant tumor | cells in serous effusions with an automatic hematology analyzer |
| using a n | novel diagnostic algorithm              |            |   |
| Manuscr   | ript number (if known):                 | 2998       |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:2022/       | /01/20                 |                 |                          |                  |                     |
|------------------|------------------------|-----------------|--------------------------|------------------|---------------------|
| Your Name:       | Taixue An              |                 |                          |                  |                     |
| Manuscript Title | e: Screening for malig | nant tumor cell | s in serous effusions wi | ith an automatic | hematology analyzer |
| using a novel di | agnostic algorithm     |                 |                          |                  |                     |
| Manuscript nun   | nber (if known):       | 2998            |                          |                  |                     |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:2      | 2022/01/20                    |  |     |
|-------------|-------------------------------|--|-----|
| Your Name   | e:Xiaojing He                 |  |     |
| Manuscrip   | ot Title: Screening for malig | ant tumor cells in serous effusions with an automatic hematology analy | zer |
| using a nov | vel diagnostic algorithm      |  |     |
| Manuscrip   | ot number (if known):         |  |     |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | None   |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | None   |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | None   |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | None   |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:202      | 22/01/20   |                |
|---------------|--|----------------|
| Your Name:    | Kai Qiu  |                |
| Manuscript Ti | itle: Screening for malignant tumor cells in serous effusions with an automatic hemato | ology analyzer |
| using a novel | l diagnostic algorithm   |                |
| Manuscript n  | number (if known): <u>2998_</u>  |                |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:     | _2022/01/20   |
|-----------|---|
| Your Nar  | ne:Yuhong Luo   |
| Manuscr   | pt Title: Screening for malignant tumor cells in serous effusions with an automatic hematology analyzer |
| using a n | ovel diagnostic algorithm   |
| Manuscr   | pt number (if known): <u>2998</u>   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:2022/01        | /20   |
|---------------------|---|
| Your Name:2         | Zheyuan Qin   |
| Manuscript Title:   | Screening for malignant tumor cells in serous effusions with an automatic hematology analyzer |
| using a novel diagn | ostic algorithm   |
| Manuscript numbe    | r (if known):   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None   |  |
|----|--|--|--|
| 6  | Payment for expert testimony   | None   |  |
| 7  | Support for attending meetings and/or travel   | None   |  |
| 8  | Patents planned, issued or pending   | None   |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None   |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None   |  |
| 11 | Stock or stock options   | None   |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None   |  |
| 13 | Other financial or non-<br>financial interests   | Shenzhen Mindray Bio-<br>Medical Electronic Co.,<br>Ltd., Shenzhen, China. |  |

Zheyuan Qin is from Shenzhen Mindray Bio-Medical Electronic Co., Ltd., Shenzhen, China.

### Please place an "X" next to the following statement to indicate your agreement:

| Date:2022/01/20_        |  |
|-------------------------|--|
| Your Name: Yon          | gjian He   |
| Manuscript Title: Sci   | eening for malignant tumor cells in serous effusions with an automatic hematology analyzer |
| using a novel diagnosti | c algorithm  |
| Manuscript number (if   | known):2998  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:     | 2022/01/20                          |              |   |
|-----------|-------------------------------------|--------------|---|
| Your Nar  | me: <u>Tie Xiong</u>                |              |   |
| Manuscr   | ript Title: <u>Screening for ma</u> | lignant tumo | r cells in serous effusions with an automatic hematology analyzer |
| using a n | novel diagnostic algorithm          |              |   |
| Manuscr   | ript number (if known):             | 2998         |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:202      | 2/01/20   |
|---------------|---|
| Your Name:_   | Houmei Feng   |
| Manuscript T  | tle: Screening for malignant tumor cells in serous effusions with an automatic hematology analyze |
| using a novel | diagnostic algorithm  |
| Manuscript n  | umber (if known): <u>2998</u>   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:     | _2022/01/20  |
|-----------|--|
| Your Na   | me:Jin Li  |
| Manusc    | ript Title: Screening for malignant tumor cells in serous effusions with an automatic hematology analyze |
| using a r | novel diagnostic algorithm   |
| Manusc    | ript number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None   |  |
|----|--|--|--|
| 6  | Payment for expert testimony   | None   |  |
| 7  | Support for attending meetings and/or travel   | None   |  |
| 8  | Patents planned, issued or pending   | None   |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None   |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None   |  |
| 11 | Stock or stock options   | None   |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None   |  |
| 13 | Other financial or non-<br>financial interests   | Shenzhen Mindray Bio-<br>Medical Electronic Co.,<br>Ltd., Shenzhen, China. |  |

Jin Li is from Shenzhen Mindray Bio-Medical Electronic Co., Ltd., Shenzhen, China.

### Please place an "X" next to the following statement to indicate your agreement:

| Date:      | _2022/01/20   |              |
|------------|---|--------------|
| Your Nam   | ne:Lei Zheng  |              |
| Manuscrip  | ipt Title: Screening for malignant tumor cells in serous effusions with an automatic hematolo | ogy analyzer |
| using a no | ovel diagnostic algorithm   |              |
| Manuscrip  | ipt number (if known): <u>2998_</u>   |              |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | None   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | None   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,   | None |  |
|----|--|------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |      |  |
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
|    |  |      |  |
| 8  | Patents planned, issued or<br>pending  | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

None

# Please place an "X" next to the following statement to indicate your agreement: